Rafael Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. on January 10, 2019. The report details a specific corporate event involving the Company's 90%-owned subsidiary, IDT-Rafael Holdings, LLC, and its investment in Rafael Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margin, or debt metrics for Rafael Holdings, Inc. The only specific financial data disclosed relates to the transaction described below:
- Transaction Amount: $6.4 million
- Shares Purchased: 5.1 million shares of Series D Convertible Preferred Stock
- Post-Transaction Ownership: 25.0% of outstanding capital stock (15.7% on a fully diluted basis excluding remaining warrant).
Material Changes
On January 10, 2019, the subsidiary partially exercised a Warrant to purchase Series D Convertible Preferred Stock of Rafael Pharmaceuticals. This follows a previous partial exercise where 12.0 million shares were purchased. The Warrant allows for the purchase of up to 56.0% of Rafael Pharmaceuticals' equity.
Outlook, Commentary, and Risks
Use of Proceeds: Rafael Pharmaceuticals will utilize the $6.4 million proceeds to fund expenses related to Phase III clinical trials of its flagship compound, CPI-613, as well as other trial phases, research, and general corporate purposes.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard nature of clinical trial funding and equity investment.
Key Facts for Investor Verification
- Verify the current status and progress of the Phase III clinical trials for CPI-613.
- Confirm the remaining exercisable amount of the Warrant held by the subsidiary.
- Review the capitalization table of Rafael Pharmaceuticals to understand the dilution impact of the remaining Warrant.
- Assess the financial health of Rafael Pharmaceuticals to ensure the $6.4 million injection is sufficient for the stated clinical trial milestones.